Z. Tan

Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma

W. Novotny, Weili Zhao, F. Lv, 2021, Blood advances.

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.

M. Dimopoulos, C. Buske, P. Zinzani, 2020, Blood advances.

Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib.

W. Novotny, P. Marlton, A. Roberts, 2020 .

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up.

W. Novotny, P. Marlton, A. Roberts, 2020, Blood.

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma

W. Novotny, S. Opat, C. Tam, 2022, Blood advances.

69O First-line serplulimab versus placebo in combination with chemotherapy in PD-L1-positive oesophageal squamous cell carcinoma (ASTRUM-007): A randomised, double-blind, multicentre phase III study

Huiyan Jiang, M. Zhang, K. Gu, 2022, Annals of Oncology.